Out of 1,500 volunteers that participated in the US-joint Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) clinical trial test, 200 were on Monday certificated after a one year observation revealed that they did not develop any symptoms from the vaccine.
During a program held on Monday, January 18 at the Redemption Hospital, which brought together local and international staff of PREVAIL, Mr. Anthony S. Fauci, M.D., Director of the US National Institute of Allergy and Infectious Diseases (NIAID), expressed gratitude to health workers, including staff of PREVAIL, for the level of progress in the study.
“We are grateful to the volunteers for this important clinical trial and we’re encouraged by the study’s results,” said Dr. Fauci.
He said Liberians did a remarkable job in the fight against Ebola, including the test trials, and hoped that they are proud of themselves.
The test trial was very important not only for Liberia, but for the rest of the world, because Ebola is now under control and Liberia is Ebola free, Director Fauci said.
However, Ebola is a threat that is not going to disappear from the face of the earth, especially in areas where it had appeared, with reference to Liberia, Sierra Leone, Guinea and other countries in the world, warned Fauci.
“So, what we can do now is to try and prepare for the next outbreak; and hopefully, with the results, a vaccine will be developed to vaccinate and protect people against the virus,” said Fauci.
During a tour of PREVAIL’s facilities at the John F. Kennedy Medical Hospital, Mr. Fauci told the nurses and staff that the study, which included ZMapp and the survivors’ study results, will be presented at one of the biggest annual infectious disease meetings in the United States.
The clinical trial was part of efforts to slow down the spread of the deadly haemorrhagic fever (Ebola) and prevent future outbreaks. The epidemic killed more than 8,900 people in West Africa since it began more than a year ago in Guinea, Liberia and Sierra Leone.